Bristol Myers Squibb Revenue Falls on Generic Competition for Key Drug
- Investing News
admin
- 0
- 1 minute read
Revenue at Bristol Myers Squibb declined as competition from generics captured some of the sales of its popular blood cancer drug, Revlimid.
Search
Newsletter
Stock Prices
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
Investing News
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1358880761-82e600bfa20f4c2a8c48dc39cebeb0b0.jpg "<div>Accountant vs. Controller: What's the Difference?</div>")
Accountant vs. Controller: What’s the Difference?- How to Make Money With Real Estate Options
- Who Are Bank of America’s Main Competitors?
- Who Are Bank of America’s Main Competitors?
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-td-bank-cd-rates-march-2023-7482856-1d7d5a82f0ca496b9b1d63739cd7f567.jpg "TD Bank CD Rates: November 2024")
TD Bank CD Rates: November 2024- TD Bank CD Rates: November 2024
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-fidelity-cd-rates-may-2023-7496602-4e8485ac0a5349a5bb10885241012896.jpg "Fidelity CD Rates: November 2024")
Fidelity CD Rates: November 2024- Fidelity CD Rates: November 2024
- Average Profit Margin Overview in the Banking Sector
- Average Profit Margin Overview in the Banking Sector